Navigation Links
Catching cancer early by chasing it
Date:8/1/2013

WASHINGTON D.C. August 1, 2013 -- Reaching a clinic in time to receive an early diagnosis for cancer -- when the disease is most treatable -- is a global problem. And now a team of Chinese researchers proposes a global solution: have a user-friendly diagnostic device travel to the patient, anywhere in the world.

As described in the journal Biomicrofluidics, which is produced by AIP Publishing, a team led by Gang Li, Ph.D., from Shanghai Institute of Microsystem and Information Technology at the Chinese Academy of Sciences, is developing a portable device for point-of-care diagnostic testing to detect cancer at its earliest stages. It identifies cancer biomarkers, which are biological indicators of the disease that often circulate in the blood prior to the appearance of symptoms.

The new device is based on microfluidics -- a technology that has rapidly expanded over the past decade and involves miniature devices that tightly control and manipulate tiny amounts of fluids for analysis through channels at the micro- and nano-scales.

Researchers value microfluidic technology for its low cost, speedy analysis of fluids and non-turbulent flows, and small footprint, Li said.

Inexpensive and easy-to-use, the Li team's device eliminates the need for an external power supply by relying on a specially fabricated pump to sample reagents and move fluids through microchannels.

"Our device is well suited to helping early diagnosis in resource-limited settings where no mechanical pumps or power sources are readily available because it is portable, affordable, sensitive, and specific, and delivered by technology with a user-friendly analytical platform," Li said.

He noted that the specialized pump can be prepared in advance and stored in an air-tight package. To further suit it to low-tech, rural or field conditions of use, the device allows users to read results with the naked eye or a digital camera, eliminating the need for any expensive and complicated equipment.


'/>"/>

Contact: Jason Socrates Bardi
jbardi@aip.org
240-535-4954
American Institute of Physics
Source:Eurekalert

Related biology news :

1. Catching up with catch shares
2. Forensic tools for catching poachers
3. UPCI researchers target cell sleep to lower chances of cancer recurrence
4. Study highlights possible new approach to prostate cancer treatment
5. Scientists discover a molecular switch in cancers of the testis and ovary
6. New 3-D colonoscopy eases detection of precancerous lesions
7. The naked mole-rats secret to staying cancer free
8. Study finds missing piece of pediatric cancer puzzle
9. Alternative target for breast cancer drugs
10. LSUHSC researcher awarded NCI grant to study link between chronic inflammation and cancer
11. Ovarian cancer metastases influenced by factors in target tissues
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/13/2017)... 2017 Sandata Technologies, LLC, a leading ... industry, including Electronic Visit Verification™ (EVV™), announced today ... as Senior Vice President of Product Management. ... homecare experience to Sandata, where he will be ... align Sandata,s suite of solutions with the needs ...
(Date:1/12/2017)... , January 12, 2017 A new report by Allied ... that the global biometric technology market is expected to generate revenue of $10.72 billion ... Continue Reading ... Allied Market Research ...      (Logo: http://photos.prnewswire.com/prnh/20140911/647229) ...
(Date:1/6/2017)... LA JOLLA, Calif. , Jan. 6, 2017 ... Phase 1 safety studies in healthy volunteers of ... CM4620, intended to treat acute pancreatitis. ... pancreas, is typically a mild disorder, but can ... to organ failure and sepsis, where extended hospital ...
Breaking Biology News(10 mins):
(Date:1/19/2017)... -- WuXi AppTec, a leading global pharmaceutical, biotechnology ... today announced that it has acquired HD Biosciences ... contract research organization (CRO). After completion of acquisition, ... WuXi, and will continue to focus on growing ... acquisition will further strengthen WuXi,s R&D capability from ...
(Date:1/19/2017)... Switzerland (PRWEB) , ... January ... ... provider of advanced software solutions for pharmaceutical research and development (R&D), today ... expertise in omic data analysis and interpretation for the rapidly evolving field ...
(Date:1/19/2017)... and GAITHERSBURG, Md. , ... PIP) and Altimmune, Inc., a privately-held immunotherapeutics company ... a definitive agreement for the merger of PharmAthene ... investors include Novartis Venture Fund, HealthCap, Truffle Capital ... a fully-integrated and diversified immunotherapeutics company with four ...
(Date:1/19/2017)... Mass. , Jan. 19, 2017 AquaBounty ... focused on enhancing productivity in aquaculture and a majority-owned ... announces that it has completed the listing of its ... the equity subscription from Intrexon. "AquaBounty,s listing ... that will broaden our exposure to the U.S. markets ...
Breaking Biology Technology: